Ipamorelin
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Bullish but bounded GH-axis peptide: most useful for sleep quality, training recovery, and modest lean-mass preservation rather than dramatic fat loss.
Lower cortisol/prolactin burden than older GHRPs, but still an injectable GH-axis tool: watch water retention, tingling, glucose drift, product quality, and redundant secretagogue stacking.
Bullish but bounded GH-axis peptide: most useful for sleep quality, training recovery, and modest lean-mass preservation rather than dramatic fat loss. It creates short GH pulses through GHS-R1a, works best when dosing is fasted and consistent, and becomes more body-composition oriented when paired with a GHRH analog such as CJC-1295 no-DAC.
Lower hormonal side-effect burden than older GHRPs because the core animal data did not show cortisol, prolactin, ACTH, TSH, FSH, or LH elevation even at very high multiples of the GH-effective dose. The practical risks are still real: water retention, hand/wrist tingling, injection-site reactions, glucose drift in susceptible users, quality variability, and no long-term healthy-adult safety dataset.
A clean entry point into GH-secretagogue protocols: cheaper and less suppressive than exogenous HGH, easier to tolerate than GHRP-2/GHRP-6/MK-677 for hunger and prolactin/cortisol issues, but also slower and less dramatic. Best value is sleep and recovery; body-composition users should expect an 8-16 week horizon and modest returns unless the broader training, protein, and stack context is strong.
High field confidence for sleep and recovery signal within 1-4 weeks; moderate confidence for lean-mass preservation or visible recomposition over 8-16 weeks; weak confidence for ipamorelin alone as a serious fat-loss agent. Experienced users often describe it as a starter or maintenance GH-axis tool and move to HGH when they want stronger IGF-1 and body-composition effects.
Intro
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.
It was characterized in Raun et al. 1998 (European Journal of Endocrinology, PMID 9849822) as the first truly selective growth hormone (GH) secretagogue — a compound that stimulates GH release via the ghrelin receptor (GHS-R1a) without increasing ACTH, cortisol, prolactin, TSH, FSH, or LH, even at doses 200 times the effective GH-stimulating dose. This selectivity profile distinguishes ipamorelin from older GHRPs like GHRP-6 and GHRP-2, which reliably elevate cortisol and prolactin.
Ipamorelin works through the GHS-R1a pathway — the same receptor as the endogenous hormone ghrelin. GH secretion from the pituitary somatotrophs is governed by the balance between two stimulatory inputs (GHRH from the hypothalamus and ghrelin from the stomach) against somatostatin, an inhibitory hormone released in response to eating and elevated serum GH. Because ipamorelin occupies GHS-R1a while GHRH analogs occupy the GHRH receptor, combining ipamorelin with CJC-1295 (no-DAC) or tesamorelin produces synergistic GH pulse amplification through two distinct receptor pathways — this is the biological rationale for the dominant community stack.
Human pharmacokinetic data (Pharmaceutical Research 1999) established a half-life of approximately 2 hours, dose-proportional pharmacokinetics, clearance of 0.078 L/h/kg, and a maximal GH production rate of 694 mIU/L/h. The SC50 is 214 nmol/L. The short half-life means each injection produces a discrete, pulsatile GH release pattern resembling endogenous physiology rather than the continuous supraphysiologic exposure of exogenous HGH injection.
Ipamorelin's clinical development was discontinued after positive Phase II results for postoperative gastric dysmotility. All performance, body composition, and anti-aging use is off-label. Large-scale human trials for lean mass or fat loss outcomes in healthy adults do not exist.
Observed Effects
Clinical and community evidence converge on several consistent effect domains. Sleep quality improvement — typically deeper sleep, more vivid dreams, and improved sleep architecture — is the most universally reported early effect, appearing in the first 1-2 weeks across independent community logs. Recovery from training is the second most consistent benefit: reduced muscle soreness, faster return to full training capacity, and improved tissue repair are reported across multiple 6-12 week logs by certified trainers. Body composition changes (visible lean mass accrual, gradual fat reduction) require longer cycles of 8-16 weeks and tend to be modest compared to exogenous HGH or GLP-1-class compounds.
Clinical data supports the body composition direction: a meta-analysis of ghrelin receptor agonists in malnutrition (12 studies, 1,377 patients) found lean body mass +0.25 kg (WMD, 95% CI 0.07-0.42, P=0.006) and increased grip strength. These are effects in compromised, malnourished populations — the magnitude in healthy adults with optimized nutrition and training is not established by controlled trial.
A 21-day chronic rat study demonstrated that daily ipamorelin increases body weight gain without causing pituitary desensitization, unlike GHRH which caused attenuation with chronic dosing. Bone growth in rat models has also been demonstrated. Ipamorelin does not cause appetite stimulation — this is the primary practical distinction from GHRP-6, GHRP-2, and MK-677, which all produce significant hunger as a consistent side effect.
Skin elasticity improvements and hair/nail quality are reported in long-duration user logs (6-8 months) but are among the least consistent and hardest to attribute specifically to ipamorelin versus other lifestyle factors.
Field Reports
Community experience logs cluster around three primary experience categories. First: sleep quality improvement is the most consistently reported early effect.
Users across public logs and trainer reports describe vivid dreams, deeper sleep, and improved sleep continuity within 1-2 weeks of starting ipamorelin. This is the most reliable early sign of a genuine response. Second: training recovery — reduced post-exercise soreness, faster return to full capacity, and improved subjective readiness — is reported in multiple 6-8 month logs by certified trainers. Third: gradual body composition shift over 8-16 weeks, with lean mass preservation or modest accrual and fat reduction — less dramatic than marketing implies, but directionally consistent.
A certified personal trainer (NASM) who ran three cycles over 8 months (CJC-1295 + ipamorelin, 3 mg/week each) reports: Cycle 1 — improved energy and reduced soreness by week 4; Cycle 2 — maintained composition gains; Cycle 3 — skin elasticity improvements. No significant adverse events. A 6-month log by a second 46-year-old trainer documents faster recovery as the primary benefit, with sleep and gradual composition change as secondary.
Several users report ipamorelin solo (without CJC) as sufficient for sleep and recovery goals, with one public-log user specifically noting that ipamorelin alone 'did the trick' without adding CJC — suggesting the dual-stack is not mandatory for modest goals.
A common experience trajectory: weeks 1-2: sleep improvement; weeks 2-4: reduced soreness; weeks 4-8: subtle energy improvement; weeks 8-16: visible composition change if nutrition and training are optimized. Users who do not see sleep improvement by week 2 often question their product quality or injection technique.
Switching from ipamorelin to exogenous HGH is a documented community pattern — multiple experienced users describe preferring HGH for IGF-1 elevation and body composition once they move past ipamorelin's initial benefits.
Community Consensus
Ipamorelin occupies a distinct position in the GHRP hierarchy: it is the accepted entry point for GH peptide therapy when the user wants GH-axis support without the cortisol, prolactin, and appetite baggage of older GHRPs.
The community shorthand is usually "cleanest GHRP," but the useful translation is narrower: cleaner pituitary-hormone selectivity, not a no-monitoring or no-logistics compound.
The comparative verdict is consistent. Ipamorelin is favored over GHRP-2 and GHRP-6 when hunger, prolactin, or cortisol are liabilities; it is complementary to GHRH analogs such as CJC-1295 no-DAC; it is weaker than exogenous HGH when the goal is a large body-composition or IGF-1 shift. Sermorelin and tesamorelin remain relevant comparators, but the article evidence supports treating ipamorelin + CJC-1295 no-DAC as the dominant community GH peptide stack rather than treating ipamorelin alone as the ceiling.
The main community tension is not whether ipamorelin works at all; it is what kind of result counts as worth the injection burden. Sleep quality and recovery are the high-confidence wins. Visible recomposition is slower, more training- and diet-dependent, and often subtle after an 8-12 week run. That split explains the common upgrade path: users like ipamorelin as a starter or maintenance GH-axis tool, then consider HGH when they want a stronger and more measurable body-composition effect.
Age and pituitary reserve shape expectations. Younger and middle-aged users are generally assumed to have more GH-secretagogue headroom; older users may have a lower ceiling because the protocol depends on endogenous pituitary release. The GLP-1 pairing is a newer practical lane: ipamorelin is attractive during tirzepatide or semaglutide weight loss because it does not add hunger in the way MK-677 or older GHRPs can, but that use still needs glucose awareness and should not be marketed as proven lean-mass preservation in healthy adults.
Risks & Monitoring
Ipamorelin has a notably clean side effect profile relative to other GHRPs. Water retention is the most commonly reported adverse effect at higher doses (200-300 mcg 2-3x/day), reflecting the GH-mediated sodium and water retention effect shared with all GH secretagogues. Transient injection site reactions — redness, mild swelling, soreness — are common in the first 1-2 weeks and typically resolve.
Carpal tunnel-like tingling (hands, wrists, fingers) is reported at higher doses and with prolonged use, consistent with GH-mediated nerve compression from water retention in the carpal tunnel. This is a class-level effect of GH elevation and is dose-dependent — reducing frequency or dose typically resolves it.
Importantly, ipamorelin does NOT cause: cortisol elevation (verified in Raun 1998 at 200x the effective dose), prolactin elevation, ACTH stimulation, TSH changes, or gonadotropin suppression. This is its primary safety distinction from older GHRPs. It also does NOT cause the hunger stimulation associated with GHRP-6, GHRP-2, or MK-677 — a clinically relevant advantage for users managing caloric intake.
Pituitary axis: ipamorelin stimulates rather than suppresses endogenous GH production. It does not suppress the HPA axis. There is no PCT requirement after discontinuation analogous to anabolic steroid use. However, taking ipamorelin while on exogenous HGH does not preserve pituitary function — exogenous GH suppresses endogenous production and ipamorelin does not restore this (unlike HCG's role in testicular preservation during testosterone therapy).
Long-term safety in healthy adults is genuinely unknown — all clinical trial data is from diseased populations (GI dysmotility, malnutrition, growth hormone deficiency) over short durations.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
IGF-1 is the primary downstream biomarker of GH axis activation. Baseline and mid-cycle measurement confirms responsiveness and guards against supraphysiologic elevation.
GH elevation causes transient insulin resistance. Users with borderline glucose or pre-diabetes should monitor fasting glucose at weeks 4-6, especially if stacking with MK-677 or other insulin-sensitizing compounds.
Ipamorelin does not elevate cortisol, but users switching from older GHRPs may use this as a verification check. Useful if high-dose protocol is being run.
Confirmatory check in users experiencing unexpected libido changes or galactorrhea. Ipamorelin should not elevate prolactin; any elevation suggests another causative factor.
Kidney and liver baseline before starting any peptide protocol. Relevant if stacking with hepatotoxic compounds or if the user has pre-existing conditions.
Avoid With
Do not combine Ipamorelin with the following. Sorted highest-severity first.
Why:MK-677 is also a GHS-R1a agonist (24-hour oral). Combining with ipamorelin occupies the same receptor. If insulin sensitivity is a concern, the 24-hour MK-677 GH elevation plus periodic ipamorelin spikes may compound glucose metabolism effects. Monitor fasting glucose if combining.
What to do:Some users do stack these for 24-hour continuous coverage plus pulsatile boluses, but the insulin sensitivity risk is compounded. Not universally contraindicated but warrants glucose monitoring.
Why:Receptor redundancy — all three act on GHS-R1a. Stacking multiple GHRPs at the same receptor does not produce additive GH release and wastes compounds. Choose ipamorelin alone if selectivity and clean side effect profile is the priority.
What to do:The only rationale for stacking GHRPs would be if intentionally adding GHRP-6's appetite stimulation, but this directly negates ipamorelin's clean profile advantage.
Why:Exogenous HGH suppresses endogenous pituitary GH production via negative feedback. Ipamorelin stimulates pituitary release of endogenous GH — this is physiologically pointless when exogenous HGH is already suppressing the axis. Taking ipamorelin during HGH cycles does not preserve pituitary function. Some users rotate cycles rather than co-administer.
What to do:Ipamorelin cannot preserve pituitary GH production during exogenous HGH — the analogy to HCG preserving testicular function during testosterone does not apply.
Protocols By Goal
Sleep quality and recovery (most common entry): 200-300 mcg ipamorelin bedtime injection, fasted, 5 on/2 off. Solo or stacked with CJC-1295 no-DAC. Run 8 weeks minimum. Most users notice sleep improvement in week 1-2. Recovery improvements typically apparent by week 3-4.
Body composition / lean mass support: 200-300 mcg ipamorelin + 200-300 mcg CJC-1295 no-DAC, 1-2x daily (bedtime + pre-workout fasted). 12-16 week cycle. Optimized protein intake (1.6-2.2 g/kg/day) and resistance training required to convert GH pulse into meaningful body composition change.
GLP-1 co-administration (lean mass preservation during GLP-1 deficit): 200 mcg ipamorelin bedtime while on tirzepatide or semaglutide. Ipamorelin's GH stimulation supports lean mass retention during the caloric deficit driven by GLP-1 therapy. No appetite interaction (ipamorelin does not amplify hunger).
Longevity / anti-aging (lower intensity): 100-200 mcg ipamorelin bedtime, 5 on/2 off. Solo or with CJC. Focus is on sleep quality, recovery, skin/connective tissue support, and modest IGF-1 maintenance. 12-16 week cycle with extended off periods.
Age considerations: users under 50 have more robust pituitary somatotroph function and respond more strongly. Users 50-70 have declining enzymatic capacity to cleave peptides and declining pituitary reserve — response is attenuated. Users over 70 may see minimal GH secretagogue response and should consider discussing exogenous HGH with a physician.
Dosing Details
Standard community practice clusters around 200-300 mcg per injection, subcutaneously, once or twice daily.
Bedtime is the most common single-dose timing because endogenous GH peaks during slow-wave sleep; fasted pre-workout use appears as a second dose in some reports. The key timing rule is empty-stomach use because food-triggered somatostatin can blunt the GH pulse. CJC-1295 no-DAC is the common pairing because it supplies the GHRH-side signal while ipamorelin supplies the ghrelin-receptor signal. Reconstitution math and syringe-unit instructions are intentionally omitted from the public protocol field.
Stacks & Alternatives
dual-pathway GH stack (GHS-R1a + GHRH receptor), the standard combination. Synergistic GH pulse amplification.
alternative GHRH analog for the dual-pathway stack; established visceral fat reduction data adds a secondary rationale.
oral GHS-R1a agonist; stacking with ipamorelin is redundant on the same receptor pathway and unnecessary. Choose one or the other unless deliberately seeking 24-hour coverage plus pulsatile bolus.
common healing stack. Ipamorelin provides the GH/IGF-1 axis support; BPC-157 provides local tissue repair signaling. Non-interacting pathways.
another healing stack combination for joint, tendon, or connective tissue recovery goals.
emerging lean mass preservation stack during aggressive GLP-1-driven caloric restriction. Ipamorelin supports muscle retention without amplifying appetite.
Alternatives
Stack Cost
Ipamorelin is a moderate-tax GH-axis peptide: it avoids androgen suppression and older-GHRP cortisol/prolactin issues, but it still creates injection logistics, fasted-timing discipline, IGF-1/glucose monitoring, sourcing fragility, and redundancy problems with other GH secretagogues.
The article frames ipamorelin as selective and cleaner than older GHRPs, but still a GH secretagogue with downstream IGF-1 signaling and GH-mediated insulin-resistance risk. Recommended panels include IGF-1 and fasting glucose, especially with higher doses, prolonged use, MK-677, or GLP-1 weight-loss contexts.
The dosing section requires subcutaneous handling, refrigerated storage after mixing, 5-on/2-off cycling in some community protocols, and strict empty-stomach timing. The article calls fasted timing the most commonly violated protocol rule because food-triggered somatostatin can blunt the GH pulse.
Monitoring is lighter than for androgenic or direct IGF-1 compounds, but not absent: the article recommends baseline and mid-cycle IGF-1, fasting glucose during prolonged or high-dose use, and optional cortisol/prolactin checks when symptoms or prior GHRP use make verification useful.
The stacking-conflicts section mainly flags mechanistic redundancy rather than hard toxicity: avoid simultaneous GHRP-2/GHRP-6, treat MK-677 co-use as glucose-relevant and redundant, and recognize that exogenous HGH makes pituitary GH stimulation physiologically pointless.
The practicalities section says product quality varies and poor quality is a common explanation for absent early sleep response. The evidence base also mixes primary studies, research-use material, and community protocol pages, so clinical evidence must stay separated from gray-market supply claims.
- ·Do not count ipamorelin as a no-tax recovery add-on if the user cannot maintain fasted injection windows; eating near dosing directly works against the mechanism described in the article.
- ·Do not stack multiple GHS-R1a agonists casually. Choose ipamorelin, MK-677, GHRP-2, or GHRP-6 based on the desired duration and side-effect profile rather than layering same-receptor agonism.
- ·Use IGF-1 and fasting glucose context before escalating dose or extending cycles, especially when dosing twice daily, combining with MK-677, or using it during aggressive GLP-1-driven weight loss.
- ·Treat CJC-1295 no-DAC co-use as the standard dual-pathway stack, but still budget for extra peptide handling and more GH-axis response than ipamorelin alone.
- ·Do not use ipamorelin to preserve pituitary GH function during exogenous HGH; the article explicitly states this HCG analogy does not apply.
- ·Sterile peptide handling, refrigerated storage, and subcutaneous injection routine
- ·Fasted bedtime or pre-workout dosing windows with 30-60 minutes before food afterward
- ·Baseline and mid-cycle IGF-1 plus fasting glucose monitoring for prolonged or higher-dose use
- ·Source-quality review, COA preference, and expectation-setting when early sleep response is absent
- ·Stack-routing discipline between ipamorelin alone, CJC-1295 no-DAC synergy, MK-677 redundancy, and exogenous HGH replacement
The article calls ipamorelin beginner-accessible with guidance but intermediate overall because it requires injections, sterile handling, fasted timing, cycle management, and realistic expectations about slow body-composition effects.
- ·Cannot reliably dose on an empty stomach
- ·Unwilling to run any IGF-1 or glucose monitoring during extended use
- ·Trying to combine with MK-677, exogenous HGH, or multiple GH secretagogues from the first cycle
- ·Using in a tested sport where the article notes WADA prohibition
- ·Pregnant, lactating, or actively trying to conceive
The article states ipamorelin stimulates rather than suppresses endogenous GH production, has no HPG suppression, and requires no PCT. Stopping mainly removes the sleep/recovery effect and resolves dose-dependent water retention or tingling.
- ·Loss of improved sleep quality or recovery that was present during the cycle
- ·Return toward baseline GH/IGF-1 support after discontinuation
- ·Water retention or carpal tunnel-like tingling should resolve after dose reduction or stopping
- ·No PCT requirement, but users may need to stop chasing response with dose escalation if quality or timing was the real issue
Use the article's empty-stomach rule: at least 2 hours post-meal, then wait 30-60 minutes before eating after injection. Prefer bedtime if that is the easiest naturally fasted window.
Back down dose or frequency instead of pushing past the article's 300 mcg apparent saturation point. Treat persistent tingling as a reason to pause and reassess GH-axis exposure.
Pick the GH-secretagogue strategy deliberately. If combining with MK-677 for 24-hour coverage plus pulses, follow the article's glucose-monitoring caution and do not treat it as a beginner stack.
Check timing, storage, and product quality before escalating dose.
The article recommends fasting glucose monitoring because GH elevation can cause transient insulin resistance, and MK-677 or longer high-dose use can compound that burden.
The article does not mark ipamorelin as a direct cancer driver, but GH/IGF-1 axis stimulation is a poor fit for users who should avoid growth-signal amplification without clinician oversight.
The womenConsiderations section marks pregnancy contraindication and notes no established safety data for conception or pregnancy contexts.
The quick summary states ipamorelin is WADA-prohibited, so the practical cost is not just physiologic monitoring but eligibility risk.
Practical Setup
The fasted-use requirement is the most commonly missed protocol variable and the most common explanation for blunted response.
Bedtime use is often easiest because most users are naturally fasted before sleep. Product quality matters: community experience reports meaningful variation and often treats lack of sleep response in week 1-2 as a timing, storage, or quality-control question before a dose-escalation question. The 5-on/2-off cycle pattern is a community convention rather than a receptor-desensitization requirement. For glucose-sensitive users, baseline fasting glucose and HbA1c are more useful than guessing from symptoms. Ipamorelin should not be stacked casually with other GH secretagogues unless the redundancy and glucose/IGF-1 monitoring burden are intentional.
Mechanism Deep Dive
Ipamorelin binds to and activates the GHS-R1a (Growth Hormone Secretagogue Receptor type 1a), also known as the ghrelin receptor.
GHS-R1a is expressed primarily on somatotroph cells in the anterior pituitary gland, where its activation triggers intracellular signaling cascades (Gq protein → phospholipase C → IP3/DAG → calcium mobilization → exocytosis) leading to GH vesicle release.
The two-pathway GH release model is central to understanding ipamorelin's mechanism and the rationale for stacking. GHRH released from the hypothalamus acts on the GHRH receptor (Gs-coupled → adenylyl cyclase → cAMP → PKA) to prime somatotrophs and initiate GH pulsatility. Ghrelin (and mimetics like ipamorelin) acts on GHS-R1a to amplify the GH pulse. Together, GHRH + ghrelin receptor activation produces a supraadditive GH release compared to either alone — the mechanistic basis for the dominant community CJC-1295 + ipamorelin stack.
Somatostatin is the opposing inhibitory hormone. Released from the hypothalamus and gastrointestinal tract in response to elevated serum GH, elevated IGF-1, and food intake, somatostatin acts on sst2/sst5 receptors on somatotrophs to inhibit cAMP production and block GH exocytosis. This is why fasted injection timing is mechanistically essential — eating triggers somatostatin release, directly counteracting ipamorelin's GH-stimulating effect.
Ipamorelin's selectivity for GH over other pituitary hormones reflects its structural optimization: the D-amino acid substitutions (D-2-Nal at position 3, D-Phe at position 4) and C-terminal amidation reduce cross-reactivity with ACTH, prolactin, TSH, and gonadotropin pathways compared to earlier GHRPs. The Raun 1998 paper established this selectivity at 200 times the effective GH dose — no other GHRP achieves this level of pituitary selectivity.
The GI motility mechanism is distinct from the pituitary GH-stimulating mechanism. GHS-R1a is expressed throughout the enteroendocrine system; ghrelin receptor activation in the GI tract accelerates gastric emptying and intestinal motility — the basis for ipamorelin's Phase II clinical trial for postoperative ileus. The 0.03 mg/kg IV dosing in the GI trial is equivalent to approximately 2-3 mg for a 70 kg person, much higher than community SC dosing, reflecting different pharmacokinetics for IV vs. SC routes and targeting of peripheral vs. pituitary receptors.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Ipamorelin does not elevate ACTH, cortisol, prolactin, TSH, FSH, or LH even at 200 times the effective GH-stimulating dose
Raun et al. 1998, European Journal of Endocrinology, PMID 9849822 — foundational selectivity characterization
Ipamorelin PK in humans: half-life ~2 hours, clearance 0.078 L/h/kg, volume of distribution 0.22 L/kg, SC50 214 nmol/L, maximal GH production rate 694 mIU/L/h
Pharmaceutical Research 1999, Vol 16, pp 1412-1416 — human PK/PD characterization study
Ghrelin receptor agonists produce lean body mass +0.25 kg (WMD 95% CI 0.07-0.42, P=0.006) and grip strength improvement in malnutrition
Su et al. meta-analysis of ghrelin receptor agonists, 12 studies, 1377 patients — ipamorelin is one compound in this class; extrapolation to healthy adults is indirect
Ipamorelin at 0.03 mg/kg IV twice daily improved postoperative bowel function in bowel resection patients
NCT00672074, Phase 2, multicenter, randomized, double-blind, placebo-controlled; Int J Colorectal Disease 2014. GI motility outcome, not body composition
Daily ipamorelin for 21 days in rats increased body weight without pituitary desensitization
21-day chronic rat study — key finding is absence of GH response desensitization, unlike GHRH which caused desensitization with chronic use
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.